# Mayne Pharma

> Australian multinational pharmaceutical company

**Wikidata**: [Q104481098](https://www.wikidata.org/wiki/Q104481098)  
**Source**: https://4ort.xyz/entity/mayne-pharma

## Summary
Mayne Pharma is an Australian multinational pharmaceutical company operating as a public entity on the Australian Securities Exchange. Founded in 1845, it is headquartered in Salisbury, Australia, and specializes in the research, development, and commercialization of pharmaceutical products.

## Key Facts
- **Official Name**: Mayne Pharma Group Limited  
- **Inception**: 1845  
- **Headquarters**: Salisbury, Australia (coordinates: -34.784°N, 138.651°E)  
- **Classification**: Public company and pharmaceutical company  
- **Stock Exchange**: Australian Securities Exchange (ASX) since June 29, 2007  
- **Market Capitalization**: A$555,924,838 (as of November 18, 2021)  
- **Country of Origin**: Australia  
- **Aliases**: Mayne Pharma Group Limited, Mayne Pharma (Australia)  
- **Website**: https://www.maynepharma.com/ (English language)  
- **Structured Identifiers**:  
  - ROR ID: 023s4zc74  
  - GRID ID: grid.509654.b  
  - Scilit Organization ID: 99246  
  - Crunchbase Organization ID: mayne-pharma  

## FAQs
**What is Mayne Pharma's full legal name?**  
Mayne Pharma Group Limited is its official name, as listed on the Australian Securities Exchange.  

**Where is Mayne Pharma headquartered?**  
The company is headquartered in Salisbury, Australia, with precise geographic coordinates at latitude -34.784 and longitude 138.651.  

**When was Mayne Pharma founded?**  
The company was established in 1845, making it one of Australia's oldest pharmaceutical enterprises.  

**How can investors trade Mayne Pharma shares?**  
It is publicly traded on the Australian Securities Exchange (ASX) under the ticker MYX since June 29, 2007.  

**What distinguishes Mayne Pharma from private pharmaceutical firms?**  
As a public company, it offers securities to the general public and must adhere to strict regulatory disclosure standards, unlike private firms.  

## Why It Matters
Mayne Pharma plays a critical role in Australia’s healthcare sector by developing and distributing essential pharmaceutical products. Its status as a publicly traded company enables large-scale capital formation for research and expansion, directly impacting drug accessibility and innovation. The company’s multinational operations and century-long history underscore its significance in global pharmaceutical markets, while its public listing ensures transparency and accountability to investors and regulatory bodies.  

## Notable For  
- **Longevity**: Operating continuously since 1845, making it one of Australia’s oldest pharmaceutical companies.  
- **Public Market Access**: First listed on the ASX in 2007, facilitating broad investor participation.  
- **Multinational Scope**: Functions as a global entity despite its Australian origins.  
- **Regulatory Compliance**: Adheres to stringent public company disclosure requirements, enhancing market trust.  
- **Market Presence**: Maintains a substantial market capitalization exceeding A$555 million as of 2021.  

## Body  
### Official Name and Aliases  
Mayne Pharma operates under the legal name **Mayne Pharma Group Limited**. It is also known by aliases including **Mayne Pharma (Australia)** and **Mayne Pharma Group Limited**, reflecting its regional branding and corporate structure.  

### Classification and Type  
The entity is classified as both a **public company** and a **pharmaceutical company**. As a public company, it offers securities to the general public through the Australian Securities Exchange, distinguishing it from private enterprises. Its core business focuses on pharmaceutical research, development, and commercialization.  

### History and Inception  
Founded in **1845**, Mayne Pharma boasts a 178-year history, positioning it among Australia’s longest-standing pharmaceutical firms. Its longevity underscores sustained operational resilience and industry relevance.  

### Headquarters and Operations  
Headquartered in **Salisbury, Australia**, the company’s base is geographically pinpointed at **latitude -34.784°N and longitude 138.651°E**. This location serves as the central hub for its multinational pharmaceutical operations.  

### Stock Exchange Listing  
Mayne Pharma is publicly traded on the **Australian Securities Exchange (ASX)** under the ticker symbol **MYX**. Its listing commenced on **June 29, 2007**, marking its transition to a publicly traded entity. This listing enables public investment and mandates regulatory compliance.  

### Market Capitalization  
As of **November 18, 2021**, the company’s market capitalization stood at **A$555,924,838**. This valuation reflects its financial scale and investor confidence in its pharmaceutical portfolio.  

### Online Presence  
The company maintains an official website at **https://www.maynepharma.com/**, available exclusively in **English**. This platform serves as a primary digital resource for corporate information and stakeholder engagement.  

### Identifiers and Data Links  
- **ROR ID**: 023s4zc74 (Research Organization Registry identifier)  
- **GRID ID**: grid.509654.b (Global Research Identifier Database)  
- **Scilit Organization ID**: 99246 (academic indexing identifier)  
- **Crunchbase Organization ID**: mayne-pharma (startup/tech ecosystem identifier)  
These IDs facilitate cross-referencing across academic, research, and business databases.

## References

1. GRID Release 2020-12-09
2. [Source](https://www2.asx.com.au/markets/trade-our-cash-market/directory)
3. ROR Data Dump 8.0 (April 2021)